Disulfiram (DSF) a safe, easily dosed, FDA-approved drug for the treatment of alcohol
dependence has been identified to be a potential therapeutic target for SARS-CoV-2 infection.
Disulfiram may have both antiviral (inhibiting viral replication via blocking the Mpro
protease and zinc ejection) and anti-inflammatory effects (via inhibition of NF-kB-induced
and NLRP inflammasome-induced cytokine release) on SARS-CoV-2. We will study oral disulfiram
given for 5 consecutive days (1000 mg/day in cohort 1; 2000 mg/day in cohort 2) in 60
symptomatic COVID+ individuals in a randomized (2:1) randomized, double blind
placebo-controlled trial evaluating disulfiram's effect on COVID-19 symptom severity,
SARS-CoV-2 viral load, and biomarkers of inflammation and pyroptosis (aberrant
pro-inflammatory cell death) over 31 days.